Patients
allergy, ESCC, malignancies, skin cancer, AJCC, Cancer
METASTASIS, CARDIOVASCULAR DISEASE, DISEASE, ALLERGY, MALIGNANCIES, SKIN CANCER, ONCOLOGY, ESOPHAGEAL CARCINOMA, CANCER
Our study is a phase I study of nab‐paclitaxel. From February 2019 to November 2019, 12 participants with locally advanced ESCC were enrolled in line with the eligible criteria: (1) histologically proven ESCC patients; (2) stage I to IVA disease (including metastatic cervical node), in accordance with the 8th edition of the American Joint Committee on Cancer (AJCC) staging system for esophageal carcinoma; (3) age of 18–70; (4) Eastern Cooperative Oncology Group performance status score ≤2; (5) normal functions of bone marrow, renal and liver.Key exclusion criteria included: (1) distant metastasis (clinically confirmed or suspected); (2) any treatment before enrollment (other than exploratory surgery); (3) severe cardiovascular disease; (4) known allergy to study drugs; (5) other malignancies other than non‐melanin skin cancer within 5 years.Sun Yat‐sen University Cancer Center (SYSUCC) ethics committee approved the protocol (Number B2018‐127‐01). Written informed consent was obtained from each patient. We carried out the study based on the requirements of Declaration of Helsinki. This study was registered on Chinese Clinical Trial Registry (ChiCTR1900021079).